| Tyme Technologies is a biotechnology company developing cancer metabolism-based therapies (CMBTs) that are intended to be effective across a range of solid tumors and hematologic cancers. Co.'s main clinical CMBT program, SM-88, is an oral investigational modified proprietary tyrosine derivative that is hypothesized to interrupt the metabolic processes of cancer cells by breaking down the cells' key defenses and leading to cell death through oxidative stress and exposure to the body's natural immune system. Co.'s TYME-18 is a CMBT compound under development that is delivered intratumorally. Like SM-88, TYME-18 utilizes the metabolism of cancer to create a treatment for inoperable tumors. We show 28 historical shares outstanding datapoints in our TYME shares outstanding history coverage, used to compute TYME market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing TYME market cap history over the course of time is important for investors
interested in comparing TYME's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of TYME versus a peer is one thing; comparing
TYME market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like TYME can fluctuate over the course of history.
With this page we aim to empower investors researching TYME by allowing them to research the TYME market cap history.